How to Help Your Patients Save Money on Sunosi: A Provider's Guide to Savings Programs

For prescribers who manage patients with narcolepsy or OSA-related excessive daytime sleepiness, Sunosi (solriamfetol) can be a highly effective therapeutic option — but its cost creates significant access barriers. Without insurance, a 30-day supply of Sunosi runs $1,100–$1,230. Even with insurance, prior authorization hurdles and high copays can derail treatment adherence. This guide provides a complete roadmap for helping your patients access and afford Sunosi.

The Cost Landscape: Why Sunosi Is Expensive

Sunosi is a brand-only medication — there is no FDA-approved generic version of solriamfetol, and one is not expected until approximately 2042 based on current patent protections. This means single-source pricing from Axsome Therapeutics and no generic competition to drive down costs. Insurance coverage helps most commercially insured patients, but prior authorization with step therapy requirements means significant work on your end to get coverage approved.

Program 1: Axsome Savings Card — $9 for 90 Days

The most impactful cost-reduction tool for your commercially insured patients is the Axsome Sunosi savings card, available through the SUNOSI On My Side Program.

Patient pays: As little as $9 for up to a 90-day supply

Eligibility: Must have commercial (private) health insurance; NOT valid for Medicare, Medicaid, or other government-funded programs

How it works: Applied at point of sale after insurance processes the claim. Reduces the patient's copay to approximately $9.

Requirements: Prior authorization must be approved first. The savings card reduces copay — it doesn't bypass the need for PA.

Your office staff can direct patients to sunosi.com/savings or enroll them in the program during their appointment.

Program 2: Free 30-Day Trial Voucher

For patients starting Sunosi for the first time, the Axsome free trial voucher provides 30 tablets (75 mg or 150 mg) at no cost. This is available directly at the pharmacy — patients simply present the voucher with their prescription. Key details:

One-time per patient (lifetime maximum of 30 tablets)

No insurance required — available to any patient with a valid prescription

Ideal for: bridging patients while PA is pending; patients wanting to assess tolerability before full insurance commitment

Prescribers can also request sample packs via the Axsome HCP portal at sunosihcp.com

Navigating Prior Authorization Efficiently

Prior authorization is the primary bottleneck for Sunosi access. Streamlining your PA process can get patients on medication faster and reduce administrative burden on your staff.

Documentation your team should have ready:

Sleep study results confirming narcolepsy (MSLT with polysomnography) or OSA (AHI criteria met on PSG or HSAT)

For OSA: documentation of CPAP prescription and use for at least 1 month

For OSA step therapy: pharmacy records or chart notes showing prior trial of generic modafinil and/or armodafinil with inadequate response

ICD-10 diagnosis code: G47.41 (narcolepsy) or G47.33 (OSA) — note: no specific ICD-10 code exists for EDS, use the primary diagnosis code

Letter of medical necessity if required, emphasizing functional impairment, safety risks of untreated EDS (driving, occupational hazards), and reasons standard alternatives are insufficient

Handling Prior Authorization Denials

If an initial PA is denied, don't immediately switch medications. Many denials can be successfully appealed, especially when the clinical necessity is clear. Effective appeal strategies include:

Peer-to-peer review: Request a conversation between your physician and the insurer's medical director. Clinical conversations can overturn denials that paperwork alone cannot.

Cite clinical evidence: Reference the 2023 Pitre et al. network meta-analysis (Annals of Internal Medicine) showing solriamfetol's superior efficacy versus modafinil/armodafinil for OSA-related EDS.

Emphasize safety: Untreated EDS creates real risks — driving accidents, occupational hazards. Insurers are often more responsive when patient safety is clearly documented.

Use SUNOSI On My Side resources: Axsome's dedicated support team can assist with PA submissions and appeals.

For Medicare and Medicaid Patients

The manufacturer savings card is not available to Medicare or Medicaid beneficiaries. For these patients, options include:

Medicare Part D: Coverage varies by plan. As of 2026, Part D has a $2,100 annual OOP cap for covered medications. Encourage patients to compare Part D plans during open enrollment for optimal Sunosi coverage.

Low-Income Subsidy (Extra Help): Medicare patients with limited income may qualify for Extra Help, which substantially reduces Part D costs including Sunosi copays.

Generic alternatives: For patients where cost remains prohibitive, generic modafinil (as low as $10–$40/month with coupons) may be a clinically appropriate and dramatically more affordable option.

The Axsome SUNOSI On My Side Program: Your Practice Resource

Axsome's On My Side Program is designed to support both patients and providers. Dedicated specialists can:

Handle PA submission and appeals on behalf of your practice

Enroll patients in savings programs

Identify financial assistance sources for uninsured/underinsured patients

Provide access to patient education materials

Recommending medfinder to Your Patients

Once a patient has coverage and a valid prescription, they still need to find a pharmacy with Sunosi in stock. Recommend medfinder — a service that calls pharmacies on the patient's behalf to confirm Sunosi availability and texts them the results. This is especially useful for patients with narcolepsy or OSA who may struggle with fatigue and long hold times. Also share our provider's guide to helping patients find Sunosi with your care coordination team.